Supported by 1,500 peer-reviewed studies, Bertilimumab is a first-in-class antibody which targets and lowers eotaxin-1 levels. It is being studied to see if it will improve outcomes in patients with autoimmune diseases that do not have therapies or the therapies have severe limitations, such as Bullous Pemphigoid and Crohn's & Colitis Read More 



NanomAbs is Immune's promising new-generation nanotechnology platform for cancer therapy. It is developed towards targeted, enhanced delivery of chemotherapeutics to cancer patients with potential reduction in off-target side effects. Read More 



Ceplene® immunotherapy (histamine dihydrochloride) is administered in conjunction with low dose interleukin-2 (IL-2), for maintenance of first remission in patients with Acute Myeloid Leukemia (AML). Read More 

Latest News

September 16, 2016

Immune Pharmaceuticals Signs Agreement to Fund Maxim Pharmaceuticals, Inc., its Pain and Neurology subsidiary | Read more 


PRESS RELEASE September 7, 2016

Immune Pharmaceuticals Receives $2 Million Investment in Common Stock at $0.50 per Share | Read more 


August 16, 2016

Immune Pharmaceuticals Provides Business and R&D Update and Announces Second Quarter 2016 Financial Results | Read more 


See All News 

Upcoming Events

No upcoming events found

See All Events